BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00625898
Recruitment Status : Terminated
First Posted : February 29, 2008
Last Update Posted : July 8, 2014
Cancer International Research Group (CIRG)
Hoffmann-La Roche
Genentech, Inc.
Information provided by (Responsible Party):
NSABP Foundation Inc

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : June 2013
  Study Completion Date : July 2014